IRIS
BELLI, Carmen
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.434
NA - Nord America 455
SA - Sud America 305
EU - Europa 304
AF - Africa 39
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 2.543
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 651
US - Stati Uniti d'America 422
CN - Cina 273
BR - Brasile 241
VN - Vietnam 191
HK - Hong Kong 154
IT - Italia 128
KR - Corea 54
FI - Finlandia 44
DE - Germania 41
AR - Argentina 25
NL - Olanda 25
BD - Bangladesh 16
GB - Regno Unito 15
IN - India 15
ZA - Sudafrica 14
RU - Federazione Russa 13
IQ - Iraq 12
CL - Cile 9
PK - Pakistan 9
CA - Canada 8
EC - Ecuador 8
FR - Francia 8
UZ - Uzbekistan 8
ID - Indonesia 7
KE - Kenya 7
VE - Venezuela 7
LT - Lituania 6
MA - Marocco 6
MX - Messico 6
PL - Polonia 6
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
CO - Colombia 4
CR - Costa Rica 4
GE - Georgia 4
IL - Israele 4
JO - Giordania 4
PY - Paraguay 4
TR - Turchia 4
CI - Costa d'Avorio 3
ES - Italia 3
HN - Honduras 3
JP - Giappone 3
OM - Oman 3
PE - Perù 3
UA - Ucraina 3
UY - Uruguay 3
AU - Australia 2
EG - Egitto 2
ET - Etiopia 2
GT - Guatemala 2
IE - Irlanda 2
IR - Iran 2
JM - Giamaica 2
KG - Kirghizistan 2
LB - Libano 2
NP - Nepal 2
SA - Arabia Saudita 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BO - Bolivia 1
BW - Botswana 1
CH - Svizzera 1
CM - Camerun 1
DZ - Algeria 1
GR - Grecia 1
HU - Ungheria 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MZ - Mozambico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PF - Polinesia Francese 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SE - Svezia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
VC - Saint Vincent e Grenadine 1
Totale 2.543
Salva come PNG Salva come JPEG
Città #
Singapore 259
Hong Kong 153
Boardman 106
Hefei 81
Ho Chi Minh City 72
Beijing 68
Seoul 53
Florence 48
Shanghai 42
Hanoi 39
Helsinki 39
Dallas 34
Ashburn 32
Phoenix 30
Munich 21
Ogden 21
São Paulo 17
Falkenstein 16
Haiphong 15
Amsterdam 13
Milan 13
Rio de Janeiro 12
Los Angeles 11
Rome 10
Biên Hòa 9
Da Nang 8
The Dalles 8
Belo Horizonte 7
New York 7
Tashkent 7
Santa Clara 6
Baku 5
Campinas 5
Lappeenranta 5
London 5
Warsaw 5
Amman 4
Brasília 4
Brooklyn 4
Cape Town 4
Caracas 4
Curitiba 4
Diadema 4
Goiânia 4
Gorle 4
Hải Dương 4
Johannesburg 4
Kilburn 4
Lahore 4
Nairobi 4
Paola 4
Abidjan 3
Baghdad 3
Boston 3
Buenos Aires 3
Denver 3
Dhaka 3
Frankfurt am Main 3
Guarulhos 3
Lima 3
Manchester 3
Montevideo 3
Moscow 3
New Delhi 3
Ninh Bình 3
Osasco 3
Porto Alegre 3
Quito 3
Salvador 3
Santiago 3
Tbilisi 3
Tokyo 3
Verona 3
Araçatuba 2
Atlanta 2
Bauru 2
Bishkek 2
Blumenau 2
Bologna 2
Bragança Paulista 2
Brescia 2
Bình Dương 2
Campo Largo 2
Campodarsego 2
Can Tho 2
Caxias do Sul 2
Chicago 2
Cotia 2
Dublin 2
Erbil 2
Franca 2
Governador Valadares 2
Guangzhou 2
Guarujá 2
Guatemala City 2
Guayaquil 2
Gurugram 2
Hangzhou 2
Istanbul 2
Jiaxing 2
Totale 1.462
Salva come PNG Salva come JPEG
Nome #
Variant allele frequency: a decision-making tool in precision oncology? 112
Expression of the oncoproteins p16, p53 and Ki67 as predictive value in the differentiation of low-grade intracervical neoplasms of high and low risk 78
Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women 71
Breast metastases from oligodendroglioma: An unusual extraneural spread in two young women and a review of the literature 71
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research 69
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 66
Malignant pleural mesothelioma: Current treatments and emerging drugs 65
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 63
Clinical significance of skin toxicity due to EGFR-targeted Therapies 62
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer 60
Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 60
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) 60
(Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: An open-label, randomized phase II trial 59
Targeting the microenvironment in solid tumors 59
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 59
Capecitabine with/without mitomycin C: Results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma 59
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 57
Homologous recombination deficiency in triple negative breast cancer 54
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review 53
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study) 53
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity 53
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors 53
Adjuvant treatment in biliary tract cancer: To treat or not to treat? 52
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting 52
The emerging role of PI3K inhibitors for solid tumour treatment and beyond 51
Immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer: Focus on TLR9 agonists, IMiDs and NGR-TNF 50
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial 48
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 47
Will antiangiogenic agents be a future for mesothelioma therapy? 47
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: Not just a case? 47
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data 47
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer 46
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 44
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 42
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies 42
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions 42
Liver toxicity in the era of immune checkpoint inhibitors: A practical approach 41
Neoadjuvant therapy in resectable pancreatic cancer: A critical review 40
Neo-adjuvant and adjuvant chemotherapy of gastric cancer 40
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 40
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma 39
Antiangiogenic strategies in breast cancer management 39
Malignant Mesothelioma 38
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 38
Second-line therapy in advanced biliary tract cancer: What should be the standard? 38
Progresses toward precision medicine in RET-altered solid tumors 37
Translational therapies for malignant pleural mesothelioma 37
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience 37
Mesoteliona Pleurico 37
Tumori del polmone 37
Unity is strength: One, two, or more drugs against advanced pancreatic cancer? 35
Role of taxanes in pancreatic cancer 29
Mesotelioma Pleurico 21
Totale 2.676
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.121
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.121
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023194 0 0 0 0 0 0 0 0 140 5 49 0
2023/2024200 5 1 27 8 15 6 8 32 35 13 14 36
2024/20251.006 36 114 23 42 47 106 15 70 155 31 85 282
2025/20261.276 325 116 105 200 507 23 0 0 0 0 0 0
Totale 2.676